98 results about "Ophthalmic use" patented technology

The present invention relates to collagenous membranes produced from amnion, herein referred to as a collagen biofabric. The collagen biofabric of the invention has the structural integrity of the native non-treated amniotic membrane, i.e., the native tertiary and quaternary structure. The present invention provides a method for preparing a collagen biofabric from a placental membrane, preferably a human placental membrane having a chorionic and amniotic membrane, by decellularizing the amniotic membrane. In a preferred embodiment, the amniotic membrane is completely decellularized. The collagen biofabric of the invention has numerous utilities in the medical and surgical field including for example, blood vessel repair, construction and replacement of a blood vessel, tendon and ligament replacement, wound-dressing, surgical grafts, ophthalmic uses, sutures, and others. The benefits of the biofabric are, in part, due to its physical properties such as biomechanical strength, flexibility, suturability, and low immunogenicity, particularly when derived from human placenta.

An intraocular lens comprises optical part configured to be implanted in an eye of a subject. The intraocular lens further comprises at least one aspheric surface configured, in combination with a lens in the capsular bag of an eye, to reduce an aberration of a wavefront passing the eye. The aberrations may include astigmatism, coma, and / or spherical aberrations. An aberration of the intraocular lens may be expressed as a linear combination of Zernike polynomial terms that may include a Zernike coefficient a11. The Zernike coefficient a11 may be selected to reduce a spherical aberration of a wavefront passing the eye and / or to compensate for an average value resulting from a predetermined number of estimations of the Zernike coefficient a11 in a population of corneas and capsular bag lenses.

An adaptive laser system for ophthalmic use is provided. In another aspect, a relatively inexpensive laser is employed. In another aspect of the present system, non-linear optical imaging uses multiphoton fluorescences and / or second harmonic generation, to create three-dimensional mapping of a portion of the eye in combination with automated feedback to assist with a surgical operation. In a further aspect of the present system, the patient interface uses laser induced markings or indicia to aid in focusing and / or calibration. Still another aspect employs temporal focusing of the laser beam pulse.

A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an aqueous solution, and wherein no hydrophilic organic solvent is present at a concentration greater than half of that of the cyclosporin is also disclosed herein. A composition comprising a therapeutically effective concentration of cyclosporin A and an effective amount of a vitamin E tocopherol polyethylene glycol succinate, wherein said composition is an aqueous liquid solution which is intended for ophthalmic use, and wherein no hydrophilic organic solvent is present at a mass concentration greater than or equal to that of the cyclosporin, is disclosed herein. A composition comprising a therapeutically effective concentration of cyclosporin A and an effective amount of a vitamin E tocopherol polyethylene glycol succinate, wherein said composition is an aqueous liquid solution which is intended for parenteral use, and wherein no hydrophilic organic solvent is present at a mass concentration greater than or equal to that of the cyclosporin, is disclosed herein. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.

The invention relates generally to concentrates and aqueous solutions for topical application comprising antifungal additives or agents as well as to preparation and use of such concentrates and solutions. More specifically, the invention relates to preparation and use of solutions that come in contact with the eye lids and / or eyes, such as but not limited to contact lens solutions, aqueous ophthalmic rinse solutions, and aqueous surgical scrubs for ophthalmic use.

A therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. Laennec, the active ingredient, exhibits a therapeutic effect on a wide variety of ophthalmic diseases by increasing tears and the like and is highly safe even though it is an animal-derived component. Therefore, the therapeutic agent is applicable to the prevention and / or treatment of various types of ophthalmic diseases, particularly corneal disorders, dry eye, asthenopia, inflammatorily ophthalmic diseases (e.g., meibomian gland dysfunction, Stevens-Johnson syndrome, Sjogren syndrome, uveitis) and ophthalmic diseases caused by active oxygen (e.g., cataract, glaucoma, age-related macular degeneration, optic disc atrophy).

In vivo formed matrices including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The matrix can also include a bioactive agent that can be released to provide a therapeutic effect to a patient. The formed matrices are particularly useful for treatment of the eye.

This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of tobramycin and the soft steroid loteprednol etabonate.

An ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier. The pharmaceutical composition is a safe, long-term continuously-administrable, therapeutic and / or prophylactic agent for the ophthalmologic clinical symptoms and signs in Sjögren syndrome.

An ophthalmic composition is self-emulsifying. The composition includes oil globules having an average size of less than 1 micron dispersed in an aqueous phase. These globules include a surfactant component with one or two surfactants and a polar oil component. The surfactant component and the oil component are selected to self-emulsify when mixed without mechanical homogenization. The composition also includes a disinfectant suitable for ophthalmic use, and can optionally include a therapeutic agent suitable for ophthalmic treatment.

An instrument for providing illumination of intraocular tissue during surgery generally includes a hand held light source which includes a light emitting diode, a power source for driving the diode and a control switch for interconnecting the diode with the power source. At least one fiber optic having a proximal end in light communication with the LED and a distal end size for insertion into an eye for illumination of intraocular tissue is provided.

The present invention refers to pharmaceutical formulations based on lipids for ophthalmic use comprising a phospholipid component composed of zwitterionic phospholipids of natural origin and an oily component composed of oils of natural origin emulsified in water. In particular, the invention refers to ophthalmic formulations useful, for example, for transporting drugs to the eye and in the treatment of ocular dryness, capable of restoring the lipid layer of the tear film. In particular, in a non-transitory but pathological situation such as the dry eye syndrome, such formulations also succeed in reducing the often-present inflammatory component.

Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and / or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).

An ophthalmic dispensing device having a polymer which is combined with an ophthalmic therapeutic agent in the form of a microparticle which is hypercompressed to form a controlled release dispensing device for ophthalmic use.

A multilayer polarizing structure is produced on a temporary support. The structure comprises at least one orienting layer and one polarizing layer comprising dichroic dyes, the dichroic dyes having an angular orientation determined by the orienting layer. The multilayer structure is separated from the temporary substrate before being applied onto a surface of an optical element. Applying the structure onto the optical element may be easily carried out while obtaining a quality compatible with many uses of the optical element, in particular ophthalmic use.

An adaptive laser system for ophthalmic use is provided. In another aspect, a relatively inexpensive laser is employed. In another aspect of the present system, non-linear optical imaging uses multiphoton fluorescences and / or second harmonic generation, to create three-dimensional mapping of a portion of the eye in combination with automated feedback to assist with a surgical operation. In a further aspect of the present system, the patient interface uses laser induced markings or indicia to aid in focusing and / or calibration. Still another aspect employs temporal focusing of the laser beam pulse.

Methods of using inhibitors (including monoclonal antibodies) directed against amyloid-beta peptide for the treatment of ophthalmic diseases such as age-related macular degeneration are described.

An ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier. The pharmaceutical composition is a safe, long-term continuously-administrable, therapeutic and / or prophylactic agent for the ophthalmologic clinical symptoms and signs in Sjögren syndrome.

An object of the present invention is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a chlorite. A liquid preparation for ophthalmic use containing a preservative composition for ophthalmic use comprising a chlorite and at least one stabilizer selected from the following 1) to 7): 1) creatinine; 2) geraniol; 3) glucose; 4) tocopherol acetate; 5) oxyquinoline sulfate; 6) a sugar alcohol; and 7) a polyoxyethylene sorbitan fatty acid ester can prevent the generation of chlorine dioxide, and is therefore excellent in safety and exhibits a sustained preservative effect for a prolonged period of time.

This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of an aminoglycoside and a steroid in a pharmaceutically acceptable vehicle.

The invention belongs to the technical field of medical equipment, and particularly relates to an flushing and collecting device for ophthalmic use. The flushing and collecting device is provided witheye covers; each eye cover is affixed with a sealed elastomer gasket in a surrounded mode, a connecting frame is welded between the eye covers, and the connecting frame is clamped with a nasal bridgecover; each eye cover is embedded with an eye corner spraying nozzle, the lower end of each eye cover is provided with a medicine liquid collecting trough, and the lower end of each medicine liquid collecting trough is cemented with a recycling hose; and the eye covers are clamped with a fixing belt, the fixing belt is clamped with a length adjusting buckle, and the fixing belt is fixedly suturedwith a fixing buckle. The invention can prevent medicine liquid from flowing out to wet the face by arranging sealed elastomer gaskets at the edges of the eye covers; the nasal bridge cover is arranged on the connecting frame, the concave of the nasal bridge cover is in line with the shape of the nasal bridge, so as to prevent pressure sores appearing on the nasal bridge when wearing for a long time; the used medicine liquid can be accumulated by arranging the liquid collecting troughs, preventing the dispersion of medicine liquid, so that it is not difficult to discharge the medicine liquid.

Use of L-carnitine and / or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.

The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and / or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and / or inflammation after eye surgery.

A Chinese medicine in the form of eyedrops for treating ophthalmopathy, such as cataract, presbyopia, muscae volitantes, xerophthalmia, etc, is prepared from 10 Chinese-medicinal materials including coptis root, ledebouriella root, ash bark, alum, etc through sequentially decocting, filtering, distilling, cooling and sterilizing.

The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles, aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and / or anti-infective / antibiotic / anti-fungal agents, accepted as safe and efficacious for ophthalmic use.

Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.

The invention relates to an eye gel which comprises base material, reactive Chinese medicinal components, auxiliary material and water by a mass ratio of 0.05-10.0:0.1- 40.0:1-14:50-98. The gel is capable of increasing viscosity of the active Chinese medicinal constituents, raising the retention period of the medicament in eyes, and reducing medicinal loss.

Device for packaging and dispensing drops of a substance for ophthalmic use, generally fluid, semi-fluid or in suspension, emulsion or oily solution, comprising a dispensing accessory (7) with a first valve (5) made of an elastomer material that allows the substance to pass through when the dispensing accessory (7) is stressed, without allowing outside air to pass through in the opposite direction when the dispensing accessory (7) is relaxed, characterized in that the first valve (5) is covered by a layer of Parylene.